Bone Only Mets & Measurable Lesions - Metastatic Breast Cancer Trial Talk

From the Experts

Many clinical trials for advanced breast cancer require that patients have a measurable lesion. The criteria doctors use to determine which lesions should be measured and how they are measured is called RECIST (Response Evaluation Criteria in Solid Tumors).

To help you understand these criteria, below you will find links to information about RECIST and its criteria for addressing metastatic lesions, bone only metastases and response to immunotherapy treatments.

Last Modified on February 24, 2021



for past articles or specific information.